Indaptus Therapeutics, Inc. 8-K

What Happened

• Indaptus Therapeutics, Inc. filed an 8-K on January 8, 2026, reporting that its Board increased from eight to nine members and appointed David Natan as a Class II director. Mr. Natan’s term expires at the company’s 2026 annual meeting of stockholders, when he will stand for election.
• Mr. Natan was designated by investor David E. Lazar under a securities purchase agreement dated December 22, 2025. The Board also appointed Mr. Natan to the Audit Committee and determined he meets NASDAQ’s heightened independence standards for audit committee service.

Key Details

• Board size increased from 8 to 9 members; appointment effective January 8, 2026.
• Mr. Natan will serve until the 2026 annual meeting, at which shareholders will vote on his election.
• Background: President & CEO of Natan & Associates (since 2007); prior CFO/CEO roles at public companies; CPA (inactive); B.A. in Economics from Boston University.
• Mr. Natan replaces Avraham Ben-Tzvi on the Audit Committee; Ben-Tzvi will remain a director and is intended to be engaged as a paid consultant. Mr. Natan will participate in the company’s non-employee director compensation plan.

Why It Matters

• The appointment alters board composition and adds a director with finance and public-company experience, which is relevant for corporate oversight—especially on the Audit Committee.
• Because Mr. Natan was designated under a recent securities purchase agreement, his appointment reflects investor-driven board changes tied to that agreement.
• Investors should note the term timing (subject to vote at the 2026 annual meeting), the company’s determination of Mr. Natan’s independence, and the Audit Committee change when assessing governance and oversight going forward.